Goldberg M J, Collins J F, Rowe H M, Cerimele B J
Lilly Laboratory for Clinical Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46202, USA.
J Clin Pharmacol. 1995 Feb;35(2):170-5. doi: 10.1002/j.1552-4604.1995.tb05007.x.
The dorsal hand vein distention technique has been used to study the effects of alpha-adrenergic receptor antagonists on alpha-agonist-induced venoconstriction. Using this technique, we investigated the dose-effect relationships between different intravenous routes of phentolamine (an alpha-antagonist) administration on norepinephrine (an alpha-agonist)-induced hand vein constriction. Hand vein studies were done on healthy men; each man was studied on up to four occasions. On one occasion for each man, graded doses of phentolamine were infused into a hand vein preconstricted (submaximally) with norepinephrine. The dose of phentolamine producing a half maximal response (ED50) for reversal of venoconstriction, and the maximal reversal were calculated. On the other three occasions (randomly allocated) for each man, graded doses of norepinephrine were infused into a hand vein before and during intravenous infusions of (1) control (vehicle solutions); (2) systemic (other arm vein) phentolamine; and (3) local (hand vein) phentolamine. Systemic and local phentolamine dose ratios (ED50 of norepinephrine during phentolamine, divided by ED50 of norepinephrine before phentolamine; divided by the control dose ratio) were calculated. These studies show that phentolamine (administered directly into a preconstricted hand vein) can completely reverse norepinephrine-induced venoconstriction. Phentolamine, administered by either local or systemic intravenous infusion, induces a significant rightward shift (approximately 10-fold) in responsiveness to norepinephrine-induced venoconstriction. To achieve comparable degrees of alpha-antagonism, however, systemic phentolamine must be administered intravenously at a dose approximately 3,000-fold higher than that of local phentolamine.(ABSTRACT TRUNCATED AT 250 WORDS)
手背静脉扩张技术已被用于研究α-肾上腺素能受体拮抗剂对α-激动剂诱导的静脉收缩的影响。利用该技术,我们研究了酚妥拉明(一种α-拮抗剂)不同静脉给药途径对去甲肾上腺素(一种α-激动剂)诱导的手部静脉收缩的剂量-效应关系。对健康男性进行手部静脉研究;每名男性最多接受4次研究。每名男性在其中一次研究中,将分级剂量的酚妥拉明注入已用去甲肾上腺素预收缩(次最大程度)的手部静脉。计算产生静脉收缩逆转的半数最大效应剂量(ED50)的酚妥拉明剂量以及最大逆转量。在每名男性的另外三次(随机分配)研究中,在静脉输注(1)对照(溶媒溶液)、(2)全身(另一手臂静脉)酚妥拉明和(3)局部(手部静脉)酚妥拉明之前和期间,将分级剂量的去甲肾上腺素注入手部静脉。计算全身和局部酚妥拉明的剂量比(酚妥拉明给药期间去甲肾上腺素的ED50除以酚妥拉明给药前的去甲肾上腺素的ED50;再除以对照剂量比)。这些研究表明,(直接注入预收缩的手部静脉的)酚妥拉明可完全逆转去甲肾上腺素诱导的静脉收缩。通过局部或全身静脉输注给药的酚妥拉明,可使对去甲肾上腺素诱导的静脉收缩的反应性显著右移(约10倍)。然而,为达到相当程度的α-拮抗作用,全身应用酚妥拉明的静脉给药剂量必须比局部应用酚妥拉明的剂量高约3000倍。(摘要截选至250词)